Stalicla signs CRADA deal with NIDA for mavoglurant development

Stalicla, a Swiss company specializing in the identification of specific phenotypes of autism spectrum disorder (ASD) has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH).

The agreement covers the clinical development program of mavoglurant to treat patients diagnosed with cocaine use disorder (CUD), including a Phase III study.

In January this year, Stalicla acquired worldwide rights to mavoglurant from fellow Switzerland based Novartis (NOVN: VX) for substance-use disorders, neurodevelopmental disorders, and other indications in exchange for upfront fees and equity, and development and commercial milestones of up $270 million, plus royalties on sales. Novartis has also taken an equity stake in Stalicla.